Maze Therapeutics (MAZE) Share-based Compensation (2024 - 2026)
Maze Therapeutics' Share-based Compensation history spans 3 years, with the latest figure at $7.1 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 120.37% to $7.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.3 million, a 92.04% increase, with the full-year FY2025 number at $16.4 million, up 70.02% from a year prior.
- Share-based Compensation hit $7.1 million in Q1 2026 for Maze Therapeutics, up from $6.1 million in the prior quarter.
- Over the last five years, Share-based Compensation for MAZE hit a ceiling of $7.1 million in Q1 2026 and a floor of $2.1 million in Q2 2024.
- Historically, Share-based Compensation has averaged $3.7 million across 3 years, with a median of $3.2 million in 2025.
- Biggest five-year swings in Share-based Compensation: skyrocketed 39.65% in 2025 and later surged 120.37% in 2026.
- Tracing MAZE's Share-based Compensation over 3 years: stood at $2.9 million in 2024, then soared by 113.01% to $6.1 million in 2025, then grew by 17.06% to $7.1 million in 2026.
- Business Quant data shows Share-based Compensation for MAZE at $7.1 million in Q1 2026, $6.1 million in Q4 2025, and $3.9 million in Q3 2025.